Abstract #1308: U200 Lispro Improves Glucose Control Compared to U500 Regular Insulin in Continuous Subcutaneous Insulin Infusion (CSII) in Patients with Diabetes with High Insulin Requirements

2016 ◽  
Vol 22 ◽  
pp. 329-330
Author(s):  
Wendy Lane ◽  
Stephen Weinrib ◽  
Elizabeth Pendleton ◽  
Benjamin Lane
Keyword(s):  
Glucose Control ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Regular Insulin ◽  
Subcutaneous Insulin ◽  
Insulin Requirements ◽  
Patients With Diabetes ◽  
High Insulin

Use of Continuous Subcutaneous Insulin Infusion in Young Adolescents With Diabetes Mellitus: A Case Study

1997 ◽  
Vol 23 (1) ◽  
pp. 52-54 ◽  
Author(s):  
ELIZABETH A. BOLAND ◽  
JOANN AHERN
Keyword(s):  
Metabolic Control ◽  
Growth Velocity ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Glycosylated Hemoglobin ◽  
Young Patients ◽  
Regular Insulin ◽  
Female Adolescent ◽  
Subcutaneous Insulin ◽  
Insulin Requirements

Continuous subcutaneous insulin infusion (CSII) was initiated in a young female adolescent with severe insulin resistance, decreased growth velocity, and poor metabolic control. The patient's insulin dose had been 3 u/kg/day, and it was hypothesized that her insulin requirements would be much less when only regular insulin was used. Because of the potential risk of severe hypoglycemia from giving regular insulin in amounts equivalent to her injection total daily dose as a constant subcutaneous infusion, the patient was hospitalized to begin pump therapy. Hourly glucose levels were collected for 24 hours to determine insulin requirements with this therapy. The patient subsequently required a significantly reduced dose of insulin (1.2 u/kg/day) with CSII, and her growth velocity improved. Metabolic control based on glycosylated hemoglobin levels also improved. Insulin pump treatment proved to be a viable solution for this young adolescent who required large doses of insulin to maintain reasonable control. Challenges of using this type of therapy in young patients are discussed.

scholarly journals Effectiveness of Multiple Daily Injections or Continuous Subcutaneous Insulin Infusion for Children with Type 1 Diabetes Mellitus in Clinical Practice

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Chun-xiu Gong ◽  
Li-ya Wei ◽  
Di Wu ◽  
Bing-yan Cao ◽  
Xi Meng ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Glucose Control ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Blood Glucose Control ◽  
Insulin Dosage ◽  
Subcutaneous Insulin ◽  
Multiple Daily Injections ◽  
Hba1c Levels

Aims. To determine whether multiple daily injections (MDIs) or continuous subcutaneous insulin infusion (CSII) contributes to better glucose control in children with different type 1 diabetes duration.Methods. Subjects were grouped according to early (≤1 year after disease onset; 1A) or late (1–3 years after onset; 2A) MDIs/CSII treatment initiation. Corresponding control groups (1B, 2B) received insulin injections twice daily.Results. HbA1c levels were consistently lower in group 1A than in group 1B (6 months (T2): 7.37% versus 8.21%; 12 months (T3): 7.61% versus 8.41%; 24/36 months (T4/T5): 7.61% versus 8.72%; allP<0.05), but were lower in group 2A than in group 2B only at T2 (8.36% versus 9.19%;P=0.04). Levels were lower in group 1A than in group 2A when disease duration was matched (7.61% versus 8.49%;P<0.05). Logistic regression revealed no correlation between HbA1c level and MDIs/CSII therapy. HbA1c levels were only negatively related to insulin dosage.Conclusions. Blood glucose control was better in patients receiving MDIs/CSII than in those receiving conventional treatment. Early MDIs/CSII initiation resulted in prolonged maintenance of low HbA1c levels compared with late initiation. MDIs/CSII therapy should be combined with comprehensive management.

scholarly journals Psychopathology and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Francesco Rotella ◽  
Caterina Lamanna ◽  
Ilaria Dicembrini ◽  
Carlo Faravelli ◽  
Caterina Calasso ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Continuous Subcutaneous Insulin Infusion ◽  
Insulin Infusion ◽  
Consecutive Series ◽  
Subcutaneous Insulin ◽  
Symptom Checklist ◽  
Therapeutic Goals ◽  
Patients With Diabetes ◽  
Relevant Role

Aim. Continuous subcutaneous insulin infusion (CSII) is used as an option in patients with diabetes failing to multiple daily injections (MDI). Psychological factors may play a relevant role in the failure to attain therapeutic goals in patients on MDI. This could lead to an overrepresentation of psychopathology in patients treated with CSII.Methods. A consecutive series of 100 patients with type 1 diabetes was studied, collecting main clinical parameters and assessing psychopathology with the self-reported questionnaire Symptom Checklist 90-revised. Patients on CSII were then compared with those on MDI.Results. Of the 100 enrolled patients, 44 and 56 were on CSII and MDI, respectively. Among men, those on CSII were younger than those on MDI; conversely, no difference in age was observed in women. Women on CSII showed higher scores on most Symptom Checklist 90 subscales than those on MDI, whereas no differences were observed in men.Conclusion. Women with type 1 diabetes treated with CSII display higher levels of psychopathology than those on MDI. This is probably the consequence of the fact that patients selected for CSII are those failing to MDI. Higher levels of psychopathology could represent a limit for the attainment and maintenance of therapeutic goals with CSII.

Sign in / Sign up

Export Citation Format

Share Document